Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of INV-001 Administration for the Prevention of Scar After Thyroidectomy

NCT05838833 is registered in ClinicalTrials.gov with Innovo Therapeutics, Inc. as lead sponsor.

NCT NCT05838833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05838833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of INV-001 Administration for the Prevention of Scar After Thyroidectomy
Lead sponsor
Innovo Therapeutics, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
February 14, 2023
Completion date
June 30, 2024
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

scar